

Freedom of Information Act 2000 - Request Reference FoI/22/608

Lung Cancer

Information Requested:

Please find below a freedom of information request relating to the diagnosis and treatment of non-small cell lung cancer.

Question 1: Does Cardiff & Vale University Health Board have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?	Yes	No
	<i>If Yes please provide a copy.</i>	

National Optimal Lung cancer pathway is followed. Please see attached.

Question 2: Does Cardiff & Vale University Health Board have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?		
	Yes	No
Sotorasib (Lumykras)	<i>If yes please see question 3</i>	
Entrectinib (Rozlytrek)	Yes	No
Larotrectinib (Vitrakvi)	Yes	No
Dabrafenib (Tafinlar)	Yes	No
Trametinib (Mekinist)	Yes	No
Capmatinib (Tabrecta)	Yes	No
Tepotinib (Tepmetko)	Yes	No
Bevacizumab (Avastin)	Yes	No
Ramucirumab (Cyramza)	Yes	No
Atezolizumab (Tecentriq)	Yes	No
Durvalumab (Imfinzi)	Yes	No
Cemiplimab- (Libtayo)	Yes	No
Nivolumab (Opdivo)	Yes	No
Pembrolizumab (Keytruda)	Yes	No
Ipilimumab (Yervoy)	Yes	No
Afatinib (Giotrif)	Yes	No
Dacomitinib (Vizimpro)	Yes	No
Erlotinib (Tarceva)	Yes	No
Gefitinib (Iressa)	Yes	No
Osimertinib (Tagrisso)	Yes	No
Amivantamab (Rybrevant)	Yes	No
Mobocertinib (Exkivity)	Yes	No
trastuzumab deruxtecan (Enhertu)	Yes	No
Alectinib (Alecensa)	Yes	No

Brigatinib (Alunbrig)	Yes	No
Ceritinib (Zykadia)	Yes	No
Crizotinib (Xalkori)	Yes	No
Lorlatinib (Lorviqua)	Yes	No
Entrectinib (Rozlytrek)	Yes	No
Pralsetinib (Gavreto)	Yes	No
Selpercatinib (Retsevmo)	Yes	No
Nintedanib (Vargatef®)	Yes	No

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that these cases would be treated at Velindre University NHS Trust, please see below their contact that may be of use to you,

FOI.VUNHST@wales.nhs.uk

Question 3

If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?

Please refer to our response to question 2.

Question 4

Does Cardiff & Vale University Health Board have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?

Yes

~~No~~

If yes please provide a copy

Yes, as part of the National Optimal Lung Cancer Pathway. Please see attached.

Question 5

Is Cardiff & Vale University Health Board part of a Cancer alliance or network, if so which ones?

The UHB is a part of the Wales Cancer Network.